Area: Strategy
Round-Number Bids Are Costly, but Up the Odds of a Deal
Buyers of private firms signal willingness to move fast
Who Gets Venture Capital?
Experienced founders with good products still need great employees to attract early investment, study finds
Has the Term ‘Competitive Advantage’ Outlived Its Usefulness?
Popular in business schools and executive suites, it’s no longer a meaningful way to compare companies
CEO Succession: Execs Running a Subsidiary Offer a Balance Between Insider and Outsider
In an analysis of transitions from 1993 to 2017, they wrung more from operations facing tumult
Was Research — on Physicians and Noncompete Agreements — Before Its Time?
Years after a paper goes unpublished, it’s fodder for a major Federal Trade Commission proposal
When Medicare Pays, Drug Companies Employ Older Subjects in Clinical Trials
The shift lends credibility to medicines vs. trials that exclude people 65 and older
What Happens at Hotels When Laws Restrict Airbnbs?
In New York, small and budget hotels — competitors to short-term rentals — raised prices
A Case Against Experience as a Central Driver of Innovation
Are older inventors weighed down by obsolete knowledge? Young inventors don’t carry that burden
Diversity, Economic Growth and a Bug in the Research
Whether research shows benefits from diversity depends heavily on choice of study design
Why Do Startups Make International Moves?
In connection with funding, typically; those chasing money abroad tend to raise a lot more of it
Consumer Backlash to CEO Advocacy: Signaling or Act of Conscience?
An experiment seeks to isolate motivation and raises concerns for outspoken corporate leaders
Assessing Climate Disclosure as U.S. Drops Scope 3 Requirement
What emerges is a fragmented view of corporate contribution to global warming
Nursing Home Industry Profits Obscured by Related-Party Transactions
Management and real estate deals to owners’ firms siphon off most profits
$52.6 Billion: Extra Cost to Consumers of Add-On Drug Patents
The figure is a subset, not covering huge expense of extended patents on high-priced biologics like Humira